IZERVAY (Astellas Pharma Australia Pty Ltd)
Product name
IZERVAY
Date registered
Evaluation commenced
Decision date
Approval time
218 (255 working days)
Active ingredients
avacincaptad pegol
Registration type
NCE/ NBE
Indication
IZERVAY is indicated for the treatment of adult patients with Geographic Atrophy (GA) secondary to Age-Related Macular Degeneration (AMD) with an intact fovea and when central vision is threatened by GA lesion growth (see Section 5.1 Pharmacodynamic properties – Clinical Trials).